Anti-Kappa BV605

BD Horizon™ Anti-Kappa BV605

Name: Anti-Kappa BV605
Brand: Anti-Kappa BV605
SKU: 663192

クローン TB28-2 (RUO)

Spectrum Viewer

Protocol Library

Scientific Resources

カタログ番号:663192

希望小売価格:¥102,000

単位:EA (1 Each)

容量:

100 Tests

数量:

見積に追加

見積リストに保存バルク試薬見積の依頼

製品詳細

Brand: BD Horizon™

Alternative Name: IGKC

Reactivity: Human

Isotype: Mouse BALB/c X C57BL/6 IgG1, κ

Immunogen: Human

Concentration: 200 μg/mL

Vol. Per Test: 5 μL

Entrez Gene ID: 3514,931

Regulatory Status: RUO

663192 Rev. 1

抗体の詳細

TB28-2

The Anti-Kappa antibody, clone TB28-2, is derived from the hybridization of P3-X63-AG8.653 mouse myeloma cells with spleen cells isolated from CB6F1/J (C57BL/6J × BALB/cJ) mice immunized with human IgG, κ myeloma protein.

The Anti-Kappa antibody specifically recognizes kappa (κ) light chains of human immunoglobulins.

663192 Rev. 1

フォーマットの詳細

BV605

The BD Horizon Brilliant Violet™ 605 (BV605) dye is part of the BD Horizon Brilliant Violet™ family of dyes. This tandem fluorochrome is comprised of a BV421 donor with an excitation maximum (Ex Max) of 407-nm and an acceptor dye with an emission maximum (Em Max) at 605-nm. BV605, driven by BD innovation, is designed to be excited by the violet laser (405-nm) and detected using an optical filter centered near 610-nm (e.g., a 610/20-nm bandpass filter). The acceptor dye can be excited by the yellow-green (561-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.

フォーマット: BV605

励起源: Violet 405 nm

最大励起波長: 407 nm

最大蛍光波長: 605 nm

663192 Rev.1

引用＆参考文献

No Citations Are Available for this Product

663192 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.